Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | GCK | P35557 | 1/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.39 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | STIM1 | Q13586 | 2/20 | 0.36 |
| ▸ | ORAI1 | Q96D31 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16782993 | 0.91 | NPC1 (0.46) | NPC1RAB9ASMN1; SMN2KDM4EMAPT | |
| SCHEMBL16783036 | 0.91 | NPC1 (0.48) | NPC1RAB9ASMN1; SMN2KDM4EMAPT | |
| SCHEMBL16782966 | 0.90 | PDE4D (0.44) | NPC1RAB9ASMN1; SMN2KDM4EMAPT | |
| SCHEMBL16782970 | 0.90 | PDE4D (0.46) | NPC1RAB9ASMN1; SMN2KDM4EMAPT | |
| SCHEMBL16783066 | 0.89 | NPC1 (0.43) | NPC1RAB9ASMN1; SMN2KDM4EMAPT | |
| SCHEMBL16783087 | 0.87 | RAB9A (0.42) | NPC1RAB9ASMN1; SMN2KDM4EMAPT | |
| SCHEMBL16783018 | 0.86 | NPC1 (0.44) | NPC1RAB9ASMN1; SMN2KDM4EMAPT | |
| SCHEMBL16805006 | 0.86 | PTGER1 (0.51) | NPC1RAB9ASMN1; SMN2KDM4EGRM5 | |
| SCHEMBL16782950 | 0.84 | NPC1 (0.51) | NPC1RAB9ASMN1; SMN2KDM4EMAPT | |
| SCHEMBL16783044 | 0.84 | NPC1 (0.40) | NPC1RAB9ASMN1; SMN2KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015090579-A1 | PYRAZOLYL-BASED CARBOXAMIDES IV | Grünenthal GmbH (DE) | 2015-06-25 | — | — | WO | claimed |
| US-20150166505-A1 | PYRIDINYL-SUBSTITUTED PYRAZOLYL CARBOXAMIDES | Grünenthal GmbH (DE) | 2015-06-18 | — | — | US | claimed |
| WO-2015090579-A1 | PYRAZOLYL-BASED CARBOXAMIDES IV | Grünenthal GmbH (DE) | 2015-06-25 | — | — | WO | disclosed |
| WO-2015090579-A1 | PYRAZOLYL-BASED CARBOXAMIDES IV | Grünenthal GmbH (DE) | 2015-06-25 | — | — | WO | disclosed |
| US-20150166505-A1 | PYRIDINYL-SUBSTITUTED PYRAZOLYL CARBOXAMIDES | Grünenthal GmbH (DE) | 2015-06-18 | — | — | US | disclosed |
| US-20150166505-A1 | PYRIDINYL-SUBSTITUTED PYRAZOLYL CARBOXAMIDES | Grünenthal GmbH (DE) | 2015-06-18 | — | — | US | disclosed |
| US-20150166505-A1 | PYRIDINYL-SUBSTITUTED PYRAZOLYL CARBOXAMIDES | Grünenthal GmbH (DE) | 2015-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166505-A1 | PYRIDINYL-SUBSTITUTED PYRAZOLYL CARBOXAMIDES | AADAC, NLRP3, NOD2 | NPC1 599/4885RAB9A 3615/4885SMN1; SMN2 2629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.